TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06665217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
Description: Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy.
Study: NCT06667323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated health service delivery for very young adolescent girls
Description: The proposed HPV-VISION intervention will aim to increase girl-centered access to HPV vaccination and other VYA services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health post level.
Study: NCT06668090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity bike exercise
Description: Participants will do moderate intensity bike exercise for up to one hour thrice weekly for 12 weeks.
Study: NCT06614465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Rehabilitation
Description: The intervention will consist of 4 sessions of education in pain neuroscience, 4 sessions of therapeutic exercise and 4 sessions of manual therapy in the abdominopelvic area.
Study: NCT06613854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral semaglutide
Description: Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
Study: NCT04737772

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Quitline treatment as usual
Description: TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
Study: NCT06617221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Composite graft plug
Description: after tooth extraction the socket was grafted with a composite graft plug

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: after tooth extraction the socket was grafted with allograft
Study: NCT06616025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NTX-001 (PEG-Fusion)
Description: One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.
Study: NCT06617520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarillo flavor type
Description: Participants will complete a within-subjects design that varies by cigarillo smoked: tobacco flavor, concept flavor, and characterizing flavor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarillo flavor type
Description: Participants will complete a within-subjects design that varies by cigarillo smoked: tobacco flavor, concept flavor, and characterizing flavor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarillo flavor type
Description: Participants will complete a within-subjects design that varies by cigarillo smoked: tobacco flavor, concept flavor, and characterizing flavor
Study: NCT06617156

Intervention type: OTHER
Intervention: RSBI Value Evaluation
Description: Spirometer Measurement: The traditional method for calculating RSBI involves the use of a spirometer (Wright MK20; Ferraris Medical Ltd., Hertford, England), equipped with a disposable bacterial filter at the front end, connected to the artificial airway to measure the minute ventilation of the patient's spontaneous breathing over one minute.~Three Measurement Methods from the Ventilator: A. PSV at 5 cmH2O with PEEP at 5 cmH2O B. CPAP at 5 cmH2O C. CPAP at 0 cmH2O.~Electrical impedance tomography (EIT) will be secured around the patient's thorax using a silicone belt, positioned at the fifth or sixth intercostal space, with 16 evenly spaced electrodes. Measurement data will be obtained by passing a small electrical current around the chest, utilizing the principle of resistance.
Study: NCT06010238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short term variation
Description: Short term variation in computer software analysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual interpretation
Description: Visual interpretation of cardiotocography
Study: NCT06621095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib + benmelstobart + nab-paclitaxel + gemcitabine
Description: 1. Before 8 cycles, anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel + gemcitabine
Description: 1. Before 8 cycles, nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study: NCT06620497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stress free implant bar
Description: SFI bar was sectioned and adjusted on the model for more convenience and to save the time of the appointment. The bar (Cendres Metaux, Switzerland) abutments were screwed to the implant analogues.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: milled bar
Description: bar abutments were attached to the analogues and scan bodies were threaded into the bar abutments. The cast was scanned using a lab scanner (Ceramill, Amann Girrbach, Germany). The milled bar was selected from the software (Exocad DentalCAD) and designed digitally to connect the implants.
Study: NCT06622980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The educational intervention will take the form of a video explaining both general ergonomic principles and specific advice for laparoscopic surgeons. This video will be shown to surgeons at a time of their convenience and the research team will be available to answer any further questions at this time.~The educational video will cover both ergonomics principles and specific advice for laparoscopic surgeons. The principles will be relevant to any situation, including those outside the medical field. The laparoscopic-specific section will include tips for optimisation of operating theatre set-up and advice on posture and body position. The video content will be reviewed by experts experienced in surgical ergonomics education to ensure it covers all useful information and is in line with best practice.
Study: NCT06621927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The Ideal Food Pyramid, which has not been applied before, is used to observe disease activities and especially changes in intestinal microbiota in rheumatoid arthritis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (Standard treatment)
Description: We chose a control group to show the effect of the intervention we would apply to the diet group and did not apply any intervention to the control group.
Study: NCT06617871

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Alignment (MA)
Description: Primary TKA with the Medacta SpheriKA, utilizing either MA methodology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinematic Alignment (KA) Interventions:
Description: Primary TKA with the Medacta SpheriKA, utilizing either KA methodology.
Study: NCT06618820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: One dose consists of three 650 milligram (mg) capsules, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: One dose consists of three 650 milligram (mg) capsules, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose consists of three microcrystalline cellulose capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose consists of three microcrystalline cellulose capsules.
Study: NCT06668012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palomacare® vaginal gel is a medical device with CE class IIa.
Description: The duration of the study for each patient will be approximately 11-12 days and the treatment for groups A and B will be 6 days.~In a first pilot study in asymptomatic women, a tendency towards a positive effect on the composition of vaginal fluid was already observed, as assessed by diagnostic tests and classified using a Likert scale. A subsequent study showed that treatment with a different vaginal gel but with an identical concentration of ingredients from Palomacare® vaginal gel, for 21 consecutive days, is able to improve the composition of vaginal fluid.~Based on these preliminary data, it is possible to hypothesize that the action of Palomacare® vaginal gel will have a positive effect on the composition of vaginal fluid in patients affected by dysbiosis, whether asymptomatic or not.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palomacare® vaginal gel is a medical device with CE class IIa.
Description: The duration of the study for each patient will be approximately 11-12 days and the treatment for groups A and B will be 6 days.~In a first pilot study in asymptomatic women, a tendency towards a positive effect on the composition of vaginal fluid was already observed, as assessed by diagnostic tests and classified using a Likert scale. A subsequent study showed that treatment with a different vaginal gel but with an identical concentration of ingredients from Palomacare® vaginal gel, for 21 consecutive days, is able to improve the composition of vaginal fluid.~Based on these preliminary data, it is possible to hypothesize that the action of Palomacare® vaginal gel will have a positive effect on the composition of vaginal fluid in patients affected by dysbiosis, whether asymptomatic or not.
Study: NCT04737772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QL Marijuana Check-Up intervention (QL-MJCU)
Description: QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
Study: NCT04818606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement
Description: Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings.
Study: NCT06619366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coach-guided personalized depression risk communication
Description: see information in arm description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: depression risk information
Description: see information in arm description.
Study: NCT06621342

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRP Experimental
Description: All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Experimental
Description: All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.
Study: NCT06624202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) Intervention
Description: COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) includes use of practice plans and a resource booklet aligned with the National Federation for High School guidelines for contact in practice. Coaches will also attend a pre-season coaches' clinic and be paired with a peer mentor during the season.
Study: NCT06622772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valsalva assist device
Description: A valsalva assist device designed to provide the recommended resistance to exhalation at a pressure of 40 mmHg.

Intervention type: OTHER
Group type: OTHER
Intervention: standard Valsalva manoeuvre
Description: The Valsalva manoeuvre is carried out without any device.
Study: NCT06623747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 15 kcal per kg fat-free mass

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: 45 kcal per kg fat-free mass
Study: NCT06624930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioural Counselling
Description: The PA+BC group will receive a behavioural counselling support session with a QEP every two weeks during the intervention period (12 total). Of the 12 video-conferencing calls, one session will target reflective processes (instrumental/affective attitudes), five sessions will target behavioural regulation (action planning, coping planning, social support, goal setting), and four sessions will target reflexive processing (self-regulation, habit). The remaining two sessions are booster sessions to revisit topics discussed. The importance of sustaining PA for clinical outcomes (e.g., fatigue) and PA logs will be stressed. At the end of the 6-month program, an individualized PA prescription will be provided based on their fitness level (adjusted throughout) to continue achieving the PA goal for the 6-month post intervention and 1-year post intervention follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Counselling
Description: The PA+EC group will receive the same frequency of group-based and 1:1 counseling support sessions via Zoom as PA+BC participants. However, the focus will be on exercise training principles for proper PA technique, how to monitor intensity, and progress PA safely to achieve the PA guidelines.
Study: NCT06618560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Derivative application
Description: After submarginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush), implant surfaces will be conditioned for 2 min with 24% ethylene-diaminetetraacetate EDTA (PrefGel®, Institut Straumann AG). Then, the sites will be completely rinsed with saline solution and thoroughly dried with air. Repeated irrigation and air-drying will be done in the area until complete bleeding control with sterile gauzes. Then EMD (Emdogain®, Institut Straumann AG) will be gently applied with a blunt-tipped sterile syringe until overflowing from the mucosal margin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid (HA)
Description: After submarginal instrumentation of the implant surface (i.e., titanium curettes plus oscillating chitosan brush), the cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) will be will be implemented to the peri-implant pockets.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Implants allocated to the control group will be treated with the same sub-marginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush). Implant surface will be irrigated with with sterile saline.
Study: NCT06621680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins
Description: All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Description: Connective tissue massage will be applied on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week for 20 minutes each session for 12 weeks. Treatment will begin 3 days before menstruation to the 4th day of menstruation for 3 successive menstrual cycles.
Study: NCT05448365

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol
Description: The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrines
Study: NCT05121051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, buccal cell, and nasal epithelial cell samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood, buccal cell, and nasal epithelial cell samples

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout/Broccoli Seed Extract Supplement
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01896947

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: evaluating to see if 3T MRI is as effective as MR arthrogram to diagnose labral pathology
Study: NCT05013879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio(R)Tape for edema control
Description: Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
Study: NCT05954845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies
Description: Biopsies will be obtained from the right and left colon (5 biopsies per colic region)
Study: NCT06308029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth self-management support program
Description: This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle. The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher. Participants go through the eHealth program independently at their own pace. It is recommended to do this in 8-12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face rehabilitation program
Description: The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally and written. After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions. It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.
Study: NCT06499610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection
Description: At the dose of 70mg / m2, for patients homozygous for UGT1A1 \* 28, the first dose of irinotecan was adjusted to 50mg / m2,70mg / m2 if the patient tolerated during the first cycle and 70 mg / m 2 in the subsequent cycle; add 500 mL of 5% glucose injection or 0.9% sodium chloride injection for intravenous infusion within 90 minutes. On the first day of each treatment cycle.
Study: NCT05071040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based physical activity
Description: Participants will follow a strength exercise program
Study: NCT05568615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study: NCT05002374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with optokinetic stimulation
Description: Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular rehabilitation
Description: Customized vestibular rehabilitation for five consecutive days